camptothecin has been researched along with Leiomyosarcoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beach, J; Benjamin, RS; Burgess, MA; Jenkins, J; Papadopoulos, N; Patel, SR; Trent, J | 1 |
| Bolderson, E; Helleday, T; Meuth, M; Mohindra, A; Stone, J; Wells, M | 1 |
| Bauer, S; Blay, JY; Christensen, TB; Daugaard, S; Hartmann, JT; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; Schöffski, P; Van Glabbeke, M | 1 |
| Asami, K; Kaneko, M; Kishimoto, T; Matsunaga, T; Mimaya, J; Mugishima, H; Sawada, T; Suita, S; Tsuchida, Y; Yagi, K | 1 |
3 trial(s) available for camptothecin and Leiomyosarcoma
| Article | Year |
|---|---|
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Gastrointestinal Neoplasms; Humans; Leiomyosarcoma; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leiomyosarcoma; Male; Middle Aged; Prospective Studies; Sarcoma, Synovial; Treatment Outcome | 2007 |
Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Japan; Leiomyosarcoma; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Neoplasm Proteins; Neuroblastoma; Neuroectodermal Tumors, Primitive; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
1 other study(ies) available for camptothecin and Leiomyosarcoma
| Article | Year |
|---|---|
A tumour-derived mutant allele of XRCC2 preferentially suppresses homologous recombination at DNA replication forks.
Topics: Base Pair Mismatch; Camptothecin; DNA; DNA Repair; DNA Replication; DNA-Binding Proteins; Female; Genes, Reporter; Humans; Leiomyosarcoma; Mitomycin; Mutation; Recombination, Genetic; Sarcoma; Thymidine; Tumor Cells, Cultured; Uterine Neoplasms | 2004 |